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INTRODUCTION 
Glaucoma has been considered as a major cause of 
worldwide irreversible blindness [1]. About 66.8 million 
people worldwide are afflicted with glaucoma [2]. 
Glaucoma is currently recognized to be a multifactorial, 
progressive neurodegenerative disorder. It is 
characterized by the acquired death of retina ganglion 
cells (RGCSs) and loss of their axons as well as optic nerve 
atrophy and loss of neurons in the lateral geniculate 
nucleus and the visual cortex [3]. This concept 
emphasizes that several pressure-independent 
mechanisms are responsible for the development and 
progression of glaucomatous neuropathy and that high 
intra-ocular pressure (IOP) and vascular insufficiency in 
the optic nerve head are merely risk factors for the 
development of glaucoma. The central role of raised IOP 
is being questioned as many patients continue to 
demonstrate a clinically downhill course despite initial 
control of raised IOP [4].  In addition, up to one-sixth of 
patients with glaucoma develop it despite normal IOP [5]. 
Chronic heart failure is associated with lower ocular 
perfusion pressure, and glaucomatous optic nerve head 
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changes [6]. Visual field loss and RGCs death continue to 
occur in patients with well controlled intraocular 
pressures and thus, a consensus has recently been 
reached that additional treatment strategies are needed 
[7].  
In humans, the optic nerve consists of approximately one 
million axons; with the majority of the cell bodies are 
primarily located in the ganglion cell layer [8]. RGCs 
death, therefore, represents the final common pathway 
of virtually all diseases of the optic nerve including 
glaucomatous optic neuropathy. There is histological and 
electrophysiological evidence to suggest that ganglion 
cells are the sole neurons affected in glaucoma [8]. All 
animal cells are programmed for carrying out self-
destruction when they are not needed, or when 
damaged. Apoptosis is a process rather than an event. It 
has been labeled a programmed cell death, or cell 
suicide. It is not unique to RGCSs or glaucoma alone. 
Following an initial insult, the cells try to minimize or 
buffer the damage done through a variety of processes. 
Generation of “suicide triggers” could be one of the 
consequences of these processes and interactions and 
these molecules may start the process of apoptosis 
which is characterized by an orderly pattern of inter-
nucleosomal DNA fragmentation, chromosome clumping, 
cell shrinkage and membrane blebbing [9]. Abnormally 
high calcium ion concentration leads to inappropriate 
activation of complex cascades of nucleases, proteases 
and lipases. They directly attack cell constituents and 
lead to the generation of highly reactive free radicals and 
activation of the nitric oxide pathway [10]. The resulting 
interaction between intermediate compounds and free 
radicals leads to DNA nitrosylation, fragmentation and 
activation of the apoptotic program. The major causes 
for cell death following activation of NMDA (N-methyl-
D-aspartate) receptors are the influx of calcium and 
sodium into cells, the generation of free radicals 
linked to the formation of advanced glycation 
endproducts (AGEs) and/or advanced lipoxidation 
endproducts (ALEs) as well as defects in the 
mitochondrial respiratory chain [11,12]. The general 
consensus is that intracellular concentrations of calcium 
ion are increased in apoptosis [13-16]. An increase in 
intracellular calcium is neurotoxic through activation of 
calcium-dependent catabolic enzymes [17].   
The idea of treating glaucoma with neuroprotection goes 
back to the 1990s, with Weinreb and Levin [18] writing in 
Archives of Ophthalmology that, at the very least, 
neuroprotection should be an adjunctive therapy, along 
with lowering IOP. Neuroprotection and possibly 
neuroregeneration and neuro-enhancement would be 
future treatment modality [19].  The concept of 
neuroprotective therapy for glaucoma is that damage to 
retinal ganglion cells may be prevented by intervening in 
neuronal death pathways [20-22]. The right 
pharmacologic agent with a meaningful intraocular 
penetration would rationalize the neuroprotection 
strategy in glaucoma [23].  Calcium ion dependent 
intracellular mechanisms related to glaucoma were 
recently reviewed by Crish and Calkins [24].  Calcium 
channel blockers have been shown to neutralize 
glutamate-NMDA-induced intracellular calcium ion influx. 
Neuroprotective effect of calcium channel blockers 
against retinal ganglion cell damage under hypoxia was 
shown by Yamada et al. [25], and also by Garcia-Campos 
et al. [26]. 
 
HYPOTHESIS 
Understanding of the role of extracellular calcium 
transport across cell membranes in modulating various 
intracellular signaling processes, including the initiation 
of the apoptotic cascade, represents the rationale for 
interest in investigating calcium-channel blockers for 
neuroprotection in glaucoma. Calcium channel blockers 
may potentially inhibit ganglion cells and photoreceptor 
apoptosis in glaucoma representing a viable option for 
glaucomatous optic neuropathy management. 
 
DISCUSSION 
Vascular dysregulation has been implicated in primary 
open-angle glaucoma. One theory is that ischemia of the 
retina is caused by lack of adequate blood supply due to 
the squeeze experienced by the blood vessels serving the 
optic nerve and the retina as a result of the high IOP. This 
squeeze can also cause blood vessels to burst, resulting 
in hemorrhage. Calcium channel blockers are known to 
relieve the pressure on the blood vessels [27]. 
Calcium channel blockers generally dilate isolated ocular 
vessels and increase ocular blood flow in experimental 
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animals, normal humans, and patients with open-angle 
glaucoma and in patients who have vascular diseases in 
which considerable vascular tone is present [28-30]. As 
well, contrast sensitivity in patients with normal tension 
glaucoma was found ameliorated by calcium channel 
inhibition [31-32].  
In a retrospective study of normal-tension and open-
angle glaucoma patients who happened to be taking 
calcium channel blockers, Netland et al. [33] 
demonstrated a decrease in glaucoma progression 
relative to controls. Otori et al. [34] evaluated the effect 
of diltiazem on inhibition of glutamate-induced apoptotic 
retinal ganglion cell death and concluded that application 
of diltiazem does not appear to reduce apoptosis. 
Nimodipine is an isopropyl calcium channel blocker 
which readily crosses the blood-brain barrier due to its 
high lipid solubility. Its primary action is to reduce the 
number of open calcium channels in cell membranes, 
thus restricting influx of calcium ions into cells. 
Yamada et al. [25] in an experimental in vitro model 
revealed that nimodipine has a direct neuroprotective 
effect against retinal ganglion cells damage related to 
hypoxia. Michelson et al. [35] have evaluated the impact 
of nimodipine on retinal blood flow in double-blind, two-
way, crossover study of healthy subjects and found that 
orally administered at a dosage of 30 mg three times a 
day nimodipine significantly increases retinal perfusion in 
healthy subjects.   
The impact of nimodipine on ocular circulation in normal 
tension glaucoma has been evaluated in many clinical 
studies. Piltz et al. [36] have described a performance-
corrected improvement in visual field deviation and 
contrast sensitivity in patients with normal  tension 
glaucoma (NTG) and in control subjects in a prospective, 
placebo-controlled double-masked study after oral 
administration of nimodipine (30 mg twice  a day).  Wang 
et al. [37] also stated that oral administration of 
nimodipine is useful for improvement of visual field 
defect in patients with normal-tension glaucoma. Other 
authors [38] also evidenced that a single dose of 30mg 
nimodipine normalizes the significantly reduced retinal 
blood flow in NTG patients with clinical signs of 
vasospasmic hyperactivity. Luksch et al. [29] have 
examined the impact of 60 mg nimodipine in NTG 
patients two hours following oral administration. Results 
disclosed that nimodipine increased the blood flow of 
the optic nerve head by 18% and improved color-
contrast sensitivity. Thus, nimodipine is potentially useful 
calcium channel blocker for eye disorders treatment due 
to its high lipid solubility and ability to cross the blood-
brain barrier.  
Recent experimental evidence suggests that Nilvadipine 
appears to have beneficial effects on different ocular 
structures. Ogata et al. [39] have evaluated the effects of 
nilvadipine on retinal blood flow and concluded that this 
agent may directly and selectively increase retinal tissue 
blood flow, while having only minimal effect on systemic 
circulation including arterial blood pressure. Another 
experimental study conducted by Uemura and Mizota  
[40] have also advocated the use of nilvadipine for the 
treatment of glaucoma or other retinal diseases that 
have some relation to apoptosis, based on claims that 
nilvadipine has high permeability to retina and 
neuroprotective effect to retinal cells. Otori et al. [34] in 
the experimental study of different calcium channel 
blockers protective effect against glutamate 
neurotoxicity in purified retinal ganglion cells has found 
that nilvadipine significantly reduces glutamate-induced 
apoptosis. In addition to the direct effects of calcium 
channel blockers on intracellular concentrations of 
calcium ion in ganglion cells, another indirect effect is 
expected such as increased choroidal blood flow [30]. 
Several clinical trials have shown the effectiveness of 
nilvadipine in glaucoma.  
Yamamoto et al. [41], Tomita et al. [42], Niwa et al. [43]  
have found that nilvadipine reduces vascular resistance 
in distal retrobulbar arteries and significantly increases 
velocity in the central retinal artery in patients with 
normal tension glaucoma. Tomita et al. [43] also stated 
that reduced orbital vascular resistance after a 4-week 
treatment with 2 mg oral nilvadipine consequently 
increases the optic disc blood flow. Koseki et al. [30] 
conducted a randomized, placebo-controlled, double-
masked, single-center 3-year study of nilvadipine on 
visual field and ocular circulation in glaucoma with low-
normal pressure. No topical ocular hypotensive drugs 
were prescribed. The authors concluded that nilvadipine 
(2 mg twice daily) slightly slowed the visual field 
progression and maintained the optic disc rim, and the 
posterior choroidal circulation increased over 3 years in 
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patients with open-angle glaucoma with low–normal 
intraocular pressure.  
In the latest clinical trial, Araie [44] showed evidence that 
a low dose of oral nilvadipine (4mg/day) significantly 
decreased the rate of mean deviation deterioration in 
NTG patients as compared to placebo. The results of 
these studies add to the growing body of evidence that 
nilvadipine may be useful for neuroprotection in 
glaucoma.  
Thus, nilvadipine can alleviate damage at various levels 
of visual pathway [44] and is a potentially useful calcium 
channel blocker for eye disorders treatment due to its 
hydrophobic nature with high permeability to the central 
nervous system, including the retina and has the highest 
antioxidant potency among calcium channel blockers. 
Flunarizine, a potent calcium channel blocker has been 
demonstrated to enhance RGCs survival after optic nerve 
transection in mice [45]. It should be recognized that the 
neuroprotective action of flunarizine may occur partly 
because of increased blood flow to the affected tissues. 
Flunarizine is known to have vasodilatory properties and 
to improve blood flow to the optic nerve head in patients 
with low-tension glaucoma [46]. Flunarizine itself has 
been demonstrated to lower IOP in the monkey eye 
when applied topically [47]. This finding not only 
confirms the usefulness of calcium channel blockers as 
neuroprotectants, but also shows that they can be 
effective when topically applied, at least in the case of 
flunarizine. Such data support the idea that when 
topically applied to the human eye, flunarizine may 
promote survival of some retinal ganglion cells in 
glaucoma [48].  
A neuroprotective effect of another new calcium channel 
blocker–Lomerizine have been evaluated in many 
experimental and clinical studies [49-52]. 
Tamaki et al. [49] investigated the effects of lomerizine 
on the ocular tissue circulation in rabbits and on the 
circulation in the optic nerve head and choroid in healthy 
volunteers and have found that lomerizine increases 
blood velocity, and probably blood flow, in the optic 
nerve head and retina in rabbits, and it also increases 
blood velocity in the optic nerve head in healthy humans, 
without significantly altering blood pressure or heart 
rate. Evidence from the study conducted by Hara et al. 
[50] also suggested that in healthy humans, lomerizine 
increased blood velocity in the optic nerve head, without 
significantly altering blood pressure or heart rate. 
Moreover, lomerizine reduced retinal damage in rats 
both in vitro and in vivo, presumably through a calcium 
channel blocking effect via an action that may involve a 
direct protection of retinal neurons as well as an 
improvement in the ocular circulation. These results 
indicate that lomerizine may be useful as a therapeutic 
drug against ischemic retinal diseases (such as glaucoma 
and retinal vascular occlusive diseases) that involve a 
disturbance of the ocular circulation. The general 
consensus is that lomerizine do not seem to affect 
systemic hypotension [49-51].   
In an experimental study, Karim et al. [53] have found 
that lomerizine alleviates secondary degeneration of 
retinal ganglion cells induced by an optic nerve crush 
injury in the rat, presumably by improving the impaired 
axoplasmic flow. The latest experimental study [3] 
evaluated protective properties against neuronal 
degeneration within the dorsal lateral geniculate nucleus 
and superior colliculus in mice eyes evidenced that 
lomerizine reduces the retinal damage and affords some 
protection against transsynaptic neuronal degeneration 
within the visual center of the mouse brain. 
At present Santen Pharmaceutical has lomerizine in 
Phase II trials to inhibit the progression of visual field 
defects [54]. Lomerizine and nilvadipine significantly 
increased optic nerve head tissue blood velocity in the 
untreated normal monkey eyes, while significant, less of 
an increase was found in the experimental glaucomatous 
eyes [55]. 
 
CONCLUSION 
Currently, glaucoma is recognized as a multifactorial, 
progressive, neurodegenerative disorder and is 
characterized by the acquired death of retina ganglion 
cells and loss of their axons as well as optic nerve 
atrophy and loss of neurons in the lateral geniculate 
nucleus and the visual cortex. Neuroprotection as a 
pharmacological strategy to shield retinal ganglion cell 
death has been a popular approach.  
Current studies show that neuroprotection and possibly 
neuroregeneration and neuro-enhancement would be 
the future treatment modality. Calcium channel blockers 
may potentially inhibit ganglion cells and photoreceptor 
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apoptosis in glaucoma representing a viable option for 
glaucomatous optic neuropathy management. The 
proposed new drugs have shown good promise. The 
most suitable calcium channel blocker with a meaningful 
intraocular penetration would rationalize the 
neuroprotection strategy in glaucoma.  
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